Mariko Higa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mariko Higa has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Koken Ameku
Department of Respiratory Medicine, Okinawa Prefectural Nanbu Medical Center & Children's Medical Center, Okinawa, Japan
2 shared publications - Eriko Atsumi
Division of Pathology NHO Okinawa Hospital Ginowan Okinawa Japan
1 shared publication - Hidenori Kawasaki
Division of Surgery NHO Okinawa Hospital Ginowan Okinawa Japan
1 shared publication Hiroaki Masuzaki
Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology, (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, 1076 Kiyuna, Ginowan, Okinawa, 901-2720, Japan
1 shared publication- Hironobu Hoshino
Department of Surgery, National Hospital Organization, Okinawa National Hospital, Okinawa, Japan
1 shared publication Isoko Owan
Division of Pulmonary Medicine, National Hospital Organization (NHO) Okinawa Hospital, 3-20-14 Ganeko, Ginowan, Okinawa, 901-2214, Japan
1 shared publication
Latest Publications
- Open Access
- 19 August 2025
- Published by Wiley in Respirology Case Reports
- Vol. 13 (8)
Partial Response to Nivolumab and Ipilimumab in a Patient With Malignant Pleural Mesothelioma and Pre‐Existing Myasthenia Gravis Without Severe Flares or Immune‐Related Adverse Events: A Case Report
Detailed clinical data on the combination immune checkpoint inhibitor (ICI) therapy in patients with myasthenia gravis (MG) remain limited. We report a case of malignant pleural mesothelioma with previously undiagnosed ocular MG. Owing to hepatic dysfunction, reduced doses of nivolumab and ipilimumab were administered before confirmation of anti‐acetylcholine receptor (AChR) antibody positivity. MG was diagnosed based on subtle ocular symptoms and serological tests. Prophylactic intravenous immunoglobulin and an acetylcholinesterase inhibitor were administered; combination therapy was discontinued owing to the risk of MG flare, but a partial tumour response was achieved. With disease progression, nivolumab monotherapy was reintroduced, and early steroid pulse therapy was administered owing to elevated creatine kinase, again inducing a partial response. Serological screening for anti‐AChR antibodies may help prevent severe MG flares and immune‐related adverse events. With caution, dose‐reduced and limited‐exposure ICI combination therapy may be feasible in selected patients with MG under appropriate prophylactic management.
- 19 August 2025
- Published by Wiley in Respirology Case Reports
- Vol. 13 (8)
Open AccessPartial Response to Nivolumab and Ipilimumab in a Patient With Malignant Pleural Mesothelioma and Pre‐Existing Myasthenia Gravis Without Severe Flares or Immune‐Related Adverse Events: A Case Report
Detailed clinical data on the combination immune checkpoint inhibitor (ICI) therapy in patients with myasthenia gravis (MG) remain limited. We report a case of malignant pleural mesothelioma with previously undiagnosed ocular MG. Owing to hepatic dysfunction, reduced doses of nivolumab and ipilimumab were administered before confirmation of anti‐acetylcholine receptor (AChR) antibody positivity. MG was diagnosed based on subtle ocular symptoms and serological tests. Prophylactic intravenous immunoglobulin and an acetylcholinesterase inhibitor were administered; combination therapy was discontinued owing to the risk of MG flare, but a partial tumour response was achieved. With disease progression, nivolumab monotherapy was reintroduced, and early steroid pulse therapy was administered owing to elevated creatine kinase, again inducing a partial response. Serological screening for anti‐AChR antibodies may help prevent severe MG flares and immune‐related adverse events. With caution, dose‐reduced and limited‐exposure ICI combination therapy may be feasible in selected patients with MG under appropriate prophylactic management.
- 15 July 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (5) , 872-876
Extranodal natural killer/T-cell lymphoma with lung involvement in a young adult with suspected mosquito bite hypersensitivity: A case report
- 15 July 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (5) , 872-876
Extranodal natural killer/T-cell lymphoma with lung involvement in a young adult with suspected mosquito bite hypersensitivity: A case report
- Open Access
- 23 January 2018
- Published by Wiley in Case Reports in Hematology
- Vol. 2018, 1-5
Rivaroxaban Treatment for Warfarin-Refractory Thrombosis in a Patient with Hereditary Protein S Deficiency
Protein S (PS) deficiency, an autosomal dominant hereditary thrombophilia, is more prevalent in East Asian populations than in Caucasians. PS-deficient patients have historically been administered a heparin product followed by warfarin for the treatment and secondary prevention of venous thromboembolism (VTE). However, warfarin can be ineffective or causes detrimental effects in rare cases. While direct oral anticoagulants (DOACs) are being increasingly used for the treatment and prevention of VTE, their efficacy in PS-deficient patients has not been established. We describe a 91-year-old woman who presented with chronic bilateral lower leg swelling with VTE that was refractory to warfarin anticoagulation therapy for over 1 year. Her recurrent VTE was diagnosed as quantitative hereditary PS deficiency. Rivaroxaban was administered as maintenance therapy instead of warfarin; after 8 weeks, the severities of the patient’s leg swelling and venous ulcerations were significantly reduced with rivaroxaban compared to warfarin, thus demonstrating the efficacy of rivaroxaban for warfarin-refractory chronic VTE associated with hereditary PS deficiency. This case illustrates that rivaroxaban can potentially serve as therapeutic agents to treat warfarin-refractory VTE in PS-deficient patients. Further investigations are required to confirm the efficacy of rivaroxaban on the long term in this regard.
- 23 January 2018
- Published by Wiley in Case Reports in Hematology
- Vol. 2018, 1-5
Open AccessRivaroxaban Treatment for Warfarin-Refractory Thrombosis in a Patient with Hereditary Protein S Deficiency
Protein S (PS) deficiency, an autosomal dominant hereditary thrombophilia, is more prevalent in East Asian populations than in Caucasians. PS-deficient patients have historically been administered a heparin product followed by warfarin for the treatment and secondary prevention of venous thromboembolism (VTE). However, warfarin can be ineffective or causes detrimental effects in rare cases. While direct oral anticoagulants (DOACs) are being increasingly used for the treatment and prevention of VTE, their efficacy in PS-deficient patients has not been established. We describe a 91-year-old woman who presented with chronic bilateral lower leg swelling with VTE that was refractory to warfarin anticoagulation therapy for over 1 year. Her recurrent VTE was diagnosed as quantitative hereditary PS deficiency. Rivaroxaban was administered as maintenance therapy instead of warfarin; after 8 weeks, the severities of the patient’s leg swelling and venous ulcerations were significantly reduced with rivaroxaban compared to warfarin, thus demonstrating the efficacy of rivaroxaban for warfarin-refractory chronic VTE associated with hereditary PS deficiency. This case illustrates that rivaroxaban can potentially serve as therapeutic agents to treat warfarin-refractory VTE in PS-deficient patients. Further investigations are required to confirm the efficacy of rivaroxaban on the long term in this regard.
- Open Access
- 1 January 2017
- Published by Edorium Journals Pvt. Ltd. in International Journal of Case Reports and Images
- Vol. 8 (10) , 668
Spontaneous expulsion and migration of a bronchial foreign body: A flustering rare dental accident
- 1 January 2017
- Published by Edorium Journals Pvt. Ltd. in International Journal of Case Reports and Images
- Vol. 8 (10) , 668
Open AccessSpontaneous expulsion and migration of a bronchial foreign body: A flustering rare dental accident